Absci Corp (ABSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Absci Corp (ABSI) has a cash flow conversion efficiency ratio of -0.153x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.31 Million) by net assets ($171.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Absci Corp for the company's overall valuation and market capitalisation.
Absci Corp - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Absci Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Absci Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Absci Corp ranked by their cash flow conversion efficiency. See ABSI debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Ruoyuchen Information Tec
SHE:003010
|
0.373x |
|
Borr Drilling Ltd
NYSE:BORR
|
-0.022x |
|
Resilient Property Income Fund Ltd
JSE:RES
|
0.028x |
|
Shanghai Environment Group Co Ltd
SHG:601200
|
0.036x |
|
Hunan Oil Pump
SHG:603319
|
0.018x |
|
Rush Enterprises B Inc
NASDAQ:RUSHB
|
0.045x |
|
One Software Technologies Ltd
TA:ONE
|
0.082x |
|
Allied Machinery Co. Ltd.
SHG:605060
|
N/A |
Annual Cash Flow Conversion Efficiency for Absci Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Absci Corp from 2019 to 2025. View ABSI stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $189.45 Million | $-92.92 Million | -0.491x | -21.36% |
| 2024-12-31 | $179.13 Million | $-72.40 Million | -0.404x | -10.17% |
| 2023-12-31 | $176.18 Million | $-64.64 Million | -0.367x | -23.78% |
| 2022-12-31 | $274.41 Million | $-81.34 Million | -0.296x | -79.08% |
| 2021-12-31 | $366.11 Million | $-60.60 Million | -0.166x | -1.10% |
| 2020-12-31 | $67.00 Million | $-10.97 Million | -0.164x | -211.71% |
| 2019-12-31 | $-41.16 Million | $-6.03 Million | 0.147x | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more